Astellas Pharma Inc 2016 AR2
The report details Astellas' financial and non-financial performance for fiscal 2015, highlighting double-digit growth in sales and profit driven by its oncology and urology franchises. The company advanced its strategic priorities, including the acquisition of Ocata Therapeutics to establish a presence in regenerative medicine and cell therapy. Astellas also strengthened its global governance and compliance frameworks by establishing a new Ethics & Compliance organization. On the environmental front, the company achieved its water withdrawal targets and continued to reduce greenhouse gas emissions.
Company: Astellas Pharma Inc
Sector: Health Care
Country: Japan
Year: 2016
Type: AR2
Pages: 158
Astellas Pharma Inc
Annual Report
The report details Astellas' financial and non-financial performance for fiscal 2015, highlighting double-digit growth in sales and profit driven by its oncology and urology franchises. The company advanced its strategic priorities, including the acquisition of Ocata Therapeutics to establish a presence in regenerative medicine and cell therapy. Astellas also strengthened its global governance and compliance frameworks by establishing a new Ethics & Compliance organization. On the environmental front, the company achieved its water withdrawal targets and continued to reduce greenhouse gas emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Apr 1, 2015 - Mar 31, 2016
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women in Management
Employees